Andreas Strüngmann

Overview
Andreas Strüngmann is a German physician-entrepreneur, the medically-trained co-founder of the generic-pharmaceuticals company Hexal AG, and — with his identical twin brother Thomas Strüngmann — the anchor investor behind the 2008 founding of BioNTech SE. Together the brothers operate a Munich- and Zug-based family-office platform (Athos KG and Santo Holding GmbH) that has become one of Europe's most consequential dedicated life-sciences investment vehicles.
Why this entity matters
Andreas Strüngmann and his twin brother Thomas Strüngmann co-founded Hexal AG in Holzkirchen, Bavaria, in 1986 and sold it to Novartis on 21 February 2005 for approximately 5.65 billion euros — the largest private company sale in German history at the time. Three years later, in 2008, the brothers provided the foundational seed capital of approximately 150 million euros for BioNTech SE through the AT Impf 100 Beteiligungs GmbH holding vehicle. Held through eleven pre-IPO years, that position became a jointly controlled stake worth more than 50 billion US dollars at BioNTech's August 2021 market-capitalisation peak — one of the largest venture-capital returns on record and the direct enabling condition for Comirnaty (BNT162b2).
Career, company, or institutional background
Andreas Strüngmann was born in Germany in 1950 and grew up in Bavaria. He studied medicine at the University of Freiburg and at the University at Buffalo (State University of New York), earning his MD. From 1986 through the 2005 Novartis transaction he served as the medically-trained co-lead of Hexal AG, which by early 2005 was Germany's second-largest generics firm with approximately seven thousand employees, 2004 revenue of about 1.65 billion US dollars, and a 67.7 percent controlling interest in the US generics company Eon Labs. Following the Novartis exit he formalised, with his twin brother Thomas Strüngmann, a family-office structure comprising Santo Holding GmbH (Zug) and Athos Service GmbH and Athos KG (Munich), plus special-purpose investment vehicles including AT Impf 100 Beteiligungs GmbH and ATS Beteiligungsverwaltung GmbH.
Role in the startup, technology, investment, or innovation ecosystem
The Strüngmann family office is a canonical DACH dynastic patient-capital anchor — long horizons, concentrated bets, and sustained backing of a scientific founding team across multiple companies. Beyond the BioNTech position, the portfolio includes Ganymed Pharmaceuticals (Astellas exit 2016 for up to approximately 1.28 billion euros; lead asset later approved as VYLOY / zolbetuximab in 2024), WS Audiology (via the November 2014 joint acquisition of Siemens Audiology Solutions with EQT Private Equity for 2.15 billion euros), Formycon AG (26.6 percent stake following a 2022 strategic asset merger valued at approximately 650 million euros), AiCuris (2006 Bayer AG spin-off), Immatics (July 2020 PIPE, 104 million US dollars), iOmx Therapeutics (2021 Series B, 65 million euros), Glycotope (2014, 76 million US dollars), AAVantgarde Bio (2025 Series B, 141 million US dollars), AMSilk (2025, 61 million US dollars), Antheia (2025 to 2026, 80 million US dollars combined), Bambusa Therapeutics, NexWafe and SuppreMol.
Selected relationships and affiliations
Andreas Strüngmann co-founded Hexal AG with his twin brother Thomas Strüngmann, with whom he continues to invest jointly across the Athos portfolio — the family-ownership structure retains Hexal proceeds and subsequent portfolio positions as a single pool. The Strüngmann brothers together anchor Santo Holding GmbH, Athos KG, AT Impf 100 Beteiligungs GmbH and ATS Beteiligungsverwaltung GmbH. Their long-standing partnership with the scientific founding team of Uğur Şahin, Özlem Türeci and Christoph Huber began with the founding investment in Ganymed Pharmaceuticals in 2001 and continued through the BioNTech seed round in 2008 and subsequent BioNTech financing rounds. The brothers co-founded, and named for their father Ernst Strüngmann, the Ernst Strüngmann Institute for Neuroscience in Frankfurt in partnership with the Max Planck Society. Andreas Strüngmann also anchors a philanthropic foundation focused on educational initiatives and community development in South Africa's Western Cape.
Startuprad.io relevance
Andreas Strüngmann, the February 2005 Hexal-Novartis transaction, the BioNTech founding capital stack and the Athos portfolio appear across Startuprad.io editorial coverage — including the Medium companion analysis "Meet the Twin Billionaires Behind BioNTech's Success" and recurring DACH-ecosystem monthly news episodes covering the pandemic-era mRNA response and post-2023 European life-sciences deal flow. Andreas Strüngmann is a pillar entity in Startuprad.io's DACH dynastic patient-capital cluster alongside Susanne Klatten, Dietmar Hopp and Uğur Şahin.
Public source context
Public references include the https://en.wikipedia.org/wiki/Andreas_and_Thomas_Str%C3%BCngmann , https://www.wikidata.org/wiki/Q23773022 , the https://www.forbes.com/profile/andreas-struengmann/ and the https://en.wikipedia.org/wiki/Ernst_Str%C3%BCngmann_Institute .

Startuprad.io coverage of Andreas Strüngmann

Andreas Strüngmann appears in the following Startuprad.io interviews, news and analysis.

What BioNTech Reveals About Europe's Missing Deep-Tech Scale-Up Machine
Published: 27 April 2026
Last updated: 30 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/what-biontech-reveals-about-europe-s-missing-deep-tech-scale-up-machine

Why Şahin and Türeci Are Starting Again: The Founder's Dilemma After a Global Breakthrough
Published: 26 April 2026
Last updated: 30 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/why-şahin-and-türeci-are-starting-again-the-founder-s-dilemma-after-a-global-breakthrough

BioNTech Was Not a Fluke: The Long mRNA Bet Behind Germany's Global Biotech Breakthrough
Published: 25 April 2026
Last updated: 14 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/biontech-was-not-a-fluke-the-long-mrna-bet-behind-germany-s-global-biotech-breakthrough

From Scientists to Billionaires: Why the BioNTech Founder Story Is Bigger Than the Vaccine
Published: 24 April 2026
Last updated: 30 August 2026
Coverage type: Analysis
https://www.startuprad.io/post/from-scientists-to-billionaires-why-the-biontech-founder-story-is-bigger-than-the-vaccine

Meet the Twin Billionaires Behind BioNTech’s Success
Published: 7 February 2022
Last updated: 14 August 2026
Coverage type: Interview
https://www.startuprad.io/post/meet-the-twin-billionaires-behind-biontech-s-success

About this record. This is the public Level 1 layer of Startuprad.io's entity intelligence architecture. Startuprad.io's deeper entity intelligence may include extended profiles, verified relationships, source trails, historical development, monitoring, news signals, custom entity sets, and analytical relationship mapping. These deeper layers are available through Startuprad.io's research, intelligence, and enterprise services.

Need deeper entity intelligence? Startuprad.io provides extended profiles, monitored entity sets, relationship analysis, source-backed research, and custom intelligence services for companies, investors, and institutions. → https://www.startuprad.io/become-a-partner

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.

Canonical record: https://www.startuprad.io/entities/andreas-struengmann